SISRAM MED (01696) announced its interim results, with the loss attributable to shareholders of the parent company amounting to $1.155 million, a shift from profit to loss compared to the same period last year.

date
19:14 19/08/2026
avatar
GMT Eight
Furuixi Medical Technology (01696) announced its interim results for 2026, with revenue of approximately $171.4 million, an increase of 3.6% year-on-year. The loss attributable to equity holders of the parent company was $1.155 million, a turnaround from profit to loss compared to the same period last year; the loss per share was 0.25 cents.
SISRAM MED (01696) announced its mid-term results for 2026, with revenues of approximately $171.4 million, an increase of 3.6% year-on-year. The loss attributable to shareholders of the parent company was $1.155 million, turning from profit to loss year-on-year; the loss per share was 0.25 cents.